2-Fluor-histidin | 50444-78-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Fluor-histidin
• 英文别名: 2-fluoro-histidine；(2S)-2-amino-3-(2-fluoro-1H-imidazol-5-yl)propanoic acid
• CAS: 50444-78-5
• 化学式: C₆H₈FN₃O₂
• 分子量: 173.147
• InChiKey: OYHWICVZBUWSBK-BYPYZUCNSA-N

物化性质

• 沸点：
  437.5±55.0 °C(Predicted)
• 密度：
  1.529±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  92
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2933290090

文献信息

• [EN] MULTIFUNCTIONAL MEMBRANE-ACTIVE AMINOGLYCOSIDE-PEPTIDE CONJUGATES<br/>[FR] CONJUGUÉS AMINOGLYCOSIDE-PEPTIDE MULTIFONCTIONNELS À ACTIVITÉ MEMBRANAIRE
  申请人：UNIV CALIFORNIA

  公开号：WO2016025627A1

  公开（公告）日：2016-02-18

  Compositions and methods are disclosed that relate to aminoglycoside-linker-peptide (P-L-A) conjugates having unexpectedly advantageous dual-function bactericidal properties. Encompassed compounds are shown to be capable of energy independent bacterial plasma membrane disruption and to exhibit potent toxicity to bacteria including antibiotic-resistant bacteria. These and related embodiments will find uses for treating bacterial infections including overcoming antibiotic resistance.

  揭示了与氨基糖苷-连接肽（P-L-A）共轭物相关的具有意外优势双重杀菌性能的组合物和方法。所涵盖的化合物被证明能够独立于能量的细菌质膜破坏，并对包括抗生素耐药细菌在内的细菌表现出强大的毒性。这些及相关实施例将用于治疗细菌感染，包括克服抗生素耐药性。
• 4-Fluoro-5-oxypyrazole derivate and preparation thereof
  申请人：IHARA CHEMICAL INDUSTRY Co., Ltd.

  公开号：EP0052333A1

  公开（公告）日：1982-05-26

  4-Fluoro-5-oxypyrazole derivative having the formula wherein R1 represents hydrogen atom or a lower alkyl group: and R2 represents a lower alkyl or phenyl group or a phenyl group having one or more substituent of fluorine or chlorine atom or a lower alkyl or dimethylamino group as effective intermediates for agricultural and pharmaceutical chemicals.

  4-氟-5-氧吡唑衍生物，其式如下 其中 R1 代表氢原子或低级烷基：R2 代表低级烷基或苯基或具有一个或多个氟或氯原子取代基或低 级烷基或二甲基氨基的苯基，可作为农用和医药化学品的有效中间体。
• Amino acid substituted molecules
  申请人：Allozyne, Inc.

  公开号：EP2395099A2

  公开（公告）日：2011-12-14

  The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

  本发明提供了识别、修饰和生产修饰目标分子的组合物和方法，包括通过非天然氨基酸修饰的治疗分子。本发明的某些方面包括向目标分子添加化学分子的方法，以及由此产生的组合物。本发明的某些方面还涉及用于鉴定、修饰和生产本文所述修饰靶分子的试剂盒。
• Non-natural amino acid substituted polypeptides
  申请人：Allozyne, Inc.

  公开号：EP2581450A2

  公开（公告）日：2013-04-17

  The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

  本发明提供了识别、修饰和生产修饰目标分子的组合物和方法，包括通过非天然氨基酸修饰的治疗分子。本发明的某些方面包括向目标分子添加化学分子的方法，以及由此产生的组合物。本发明的某些方面还涉及用于鉴定、修饰和生产本文所述修饰靶分子的试剂盒。
• Modified factor VIII and factor IX genes and vectors for gene therapy
  申请人：Asklepios Biopharmaceutical, Inc.

  公开号：EP2848253A1

  公开（公告）日：2015-03-18

  The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.

  本发明涉及一种经过修饰和优化的因子 VIII 或因子 IX 核酸，可用于嵌合病毒载体。这种载体可用于治疗血友病。